China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut

But Competition Looms

 
• By Dexter Jie Yan
bispecific antibody
Beyond massive investment in PD-1/L1 programs, Chinese firms are now gearing up for bispecific antibodies • Source: Shutterstock

More from China

More from Focus On Asia